Evidence map›Paper›PMID 33432363›Full record

Observational studyOncology reports2021

lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis.

Yan Zhao, Qing Zhang, Hongtao Liu, Ning Wang, Xiaosan Zhang, Shujun Yang

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. FOXP2 mediates ZSCAN18 transcriptional activation to inhibit oral squamous cell carcinoma progression by blocking Hedgehog signaling.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yan ZhaoDepartment of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China.
Qing ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Hongtao LiuSchool of Life Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Ning WangHenan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Xiaosan ZhangDepartment of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China.
Shujun YangDepartment of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China.
Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing number of studies have demonstrated that long non‑coding (lnc)RNAs are associated with tumor invasion, metastasis and the prognosis of patients with a variety of different tumors. However, the roles of lncRNA prostate androgen regulated transcript 1 (PART1) in esophageal squamous cell carcinoma (ESCC) remain unknown. In the present study, reverse transcription‑quantitative PCR was performed to investigate the levels of PART1, SRY‑box transcription factor 6 (SOX6) and miR‑18a‑5p in ESCC tissues and cells. The functions of PART1 in ESCC were demonstrated using Cell Counting Kit‑8 and Matrigel assays. Promoter activity and dual‑luciferase reporter assays, RNA immunoprecipitation and western blot analyses were also used to determine the potential mechanisms of PART1 in ESCC cell lines. It was found that PART1 and SOX6 were both downregulated in ESCC tissues and cells, and their low expression levels were associated with TNM stage, lymph node metastasis and poor prognosis in patients with ESCC. Forkhead box protein P2 (FOXP2) exhibited low expression level in ESCC tissues, and its expression was positively correlated with PART1 expression level in ESCC tissues. FOXP2 was found to bind to the promoter region of PART1 to regulate its expression in ESCC cells. Functionally, PART1 overexpression suppressed cell proliferation and invasion, whereas PART1 downregulation promoted cell proliferation and invasion in the ESCC cell lines. Mechanistically, PART1 functions as a competing endogenous (ce)RNA by sponging miR‑18a‑5p, resulting in the upregulation of the downstream target gene, SOX6, coupled with the inactivation of the β‑catenin/c‑myc signaling axis, to suppress ESCC cell proliferation and invasion. In conclusion, data from the present study unveil a potential ceRNA regulatory pathway, in which PART1 affects SOX6 expression level by sponging miR‑18a‑5p, to ultimately suppress ESCC development and progression.

Indexed as

Cell Line, TumorCell ProliferationComputational BiologyDatasets as TopicEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagusFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedNeoplasm InvasivenessForkhead Transcription FactorsFOXP2 protein, humanMicroRNAsMIRN18A microRNA, humanPART-1 RNA, humanRNA, UntranslatedSOX6 protein, humanSOXD Transcription Factorsesophageal squamous cell carcinomalong non-coding RNAmicroRNA-18a-5pprostate androgen regulated transcript 1SOX6

Identifiers

PMID33432363
PMCPMC7859983
OpenAlexW3119961776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.